MD Anderson Board Review 2026: Course Overview
MD Anderson Board Review 2026 brings together malignant and non-malignant hematology with medical oncology. Designed around ABIM certification and recertification preparation, the program covers standards of care, pharmacology, molecular genetics, cancer risk assessment, transplantation, cellular therapies and supportive care. The schedule combines disease-focused teaching with question-and-answer sessions across the major examination areas.
The original six-day virtual course ran September 14–19, 2026. Its learning objectives, planning committee, selected faculty and complete daily topic list are preserved below for hematologists, oncologists and trainees. The agenda describes the source program rather than a verified recording inventory. Provider registration, live streaming, account access and bundled publisher services are separate from this file purchase.
Learning Objectives
The original provider listed the following learning objectives; reviewing files alone does not establish clinical proficiency:
- Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology.
- Utilize current standards of care for patients with cancer, blood disorders and malignancies.
- Demonstrate proficiency of knowledge in hematology and medical oncology.
- Incorporate recent advances in management of hematologic and oncologic patients.
These objectives match the official 2026 MD Anderson course objectives.
Planning Committee / Course Directors
UT MD Anderson Cancer Center
- Sharon Giordano, MD, MPH — Co-Director
- Tapan Kadia, MD — Co-Director
- Shreyaskumar Patel, MD
- Alessandra Ferrajoli, MD
- Nishin Bhadka, MD
- Felisha Estelle
Baylor College of Medicine
- Martha Mims, MD, PhD — Co-Director
These individuals are listed by MD Anderson as members of the 2026 planning committee.
Selected 2026 Faculty and Sessions
The official 2026 schedule includes faculty such as:
- Scott Kopetz, MD — Colorectal Cancer
- Jorge Cortes, MD — Chronic Myeloid Leukemia
- Raajit Rampal, MD, PhD — Myeloproliferative Neoplasms
- Tapan M. Kadia, MD — Myelodysplastic Syndrome
- Hagop M. Kantarjian, MD — Acute Lymphoblastic Leukemia
- Betty Hamilton, MD — Stem Cell Transplant Supportive Care
- Susan O’Brien, MD — Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
- Courtney D. DiNardo, MD — Acute Myeloid Leukemia
- Paolo Strati, MD — Cellular and Immune-Based Therapies
- Samuel A. Shelburne III, MD — Infectious Complications in Hematologic Malignancies
- Caitlin R. Rausch, PharmD, BCOP — Targeted Therapies in Hematologic Malignancies
These faculty-session pairings are taken directly from the published 2026 MD Anderson agenda.
Topics
-
Monday, September 14, 2026
-
Welcome and Introduction
-
Early Stage and Locally Advanced Non-Small Cell Lung Cancer
-
Metastatic Non-Small Cell Lung Cancer
-
Small Cell Lung Cancer
-
Head and Neck Cancer
-
Thyroid Cancer
-
Q & A Panel Discussion (Lung Cancer, Head and Neck Cancer, Thyroid Cancer)
-
ASH ASCO Choosing Wisely Recommendations
-
Neuro-Oncology
-
Cervical Cancer and Endometrial Cancer
-
Ovarian Cancer and Unusual Ovarian Histologies
-
Palliative Care
-
Q & A Panel Discussion (Neuro-Oncology, Gynecologic Oncology, Palliative Care)
-
Solid Tumor Q & A Session 1: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Neuro-Oncology, Gynecologic Oncology
-
-
Tuesday, September 15, 2026
-
Pharmacology I: Chemotherapy
-
Pharmacology II: Targeted Therapy (Alk, EGFR, VEGR, HER2, HH, mTOR)
-
Genetic Risk Factors
-
Sarcoma
-
Q & A Panel Discussion (Pharmacology, Genetic Risk Factors, Sarcoma)
-
Screening/Local Management of Breast Cancer
-
Systemic Treatment of Primary Breast Cancer
-
Metastatic Breast Cancer
-
Special Issues in Breast Cancer
-
Q & A Panel Discussion (Breast Cancer)
-
Solid Tumor Q & A – Session 2: Pharmacology / Genetic Risk Factors / Sarcoma / Breast Cancer
-
-
Wednesday, September 16, 2026
-
Testicular Cancer
-
Urothelial Cancer
-
Renal Cell Carcinoma
-
Prostate Cancer
-
Melanoma
-
Q & A Panel Discussion (Genitourinary Oncology, Melanoma)
-
Pancreaticobiliary Cancers / Unknown Primary
-
Gastroesophageal Cancers / Hepatocellular Carcinoma
-
Colorectal Cancer: Biology and Adjuvant Therapy
-
Metastatic Colorectal Cancer and Anal Cancer
-
Q & A Panel Discussion (Gastrointestinal Oncology)
-
Solid Tumor Q & A – Session 3: Genitourinary Oncology / Gastrointestinal Oncology / Melanoma
-
-
Thursday, September 17, 2026
-
Chronic Myeloid Leukemia
-
Myeloproliferative Neoplasms
-
Myelodysplastic Syndrome
-
Acute Lymphoblastic Leukemia
-
Stem Cell Transplant Supportive Care
-
Q & A Panel Discussion (MPN, MDS, Leukemia, SCT)
-
Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
-
Acute Myeloid Leukemia
-
Management of Cellular and Immune Based Therapies in Cancer
-
Infectious Complications in Patients with Hematologic Malignancies
-
Targeted Therapies in Hematologic Malignancies
-
Q & A Panel Discussion (Leukemia, Therapies, Infectious Complications)
-
Malignant Hematology Q & A Session
-
-
Friday, September 18, 2026
-
Classification of Lymphoma
-
Aggressive Non-Hodgkin Lymphoma
-
Indolent Non-Hodgkin Lymphoma
-
Hodgkin Lymphoma
-
Multiple Myeloma and Other Plasma Cell Dyscrasias
-
Q & A Panel Discussion (Lymphoma, Myeloma)
-
Sickle Cell Anemias, Thalassemia, and Hemoglobinopathies
-
Approach to Anemia
-
Issues in Transfusion Medicine
-
Disorders of Platelet Function
-
Thrombocytopenias
-
Q & A Panel Discussion (Red Cell Disorders, Transfusion Medicine, Platelets)
-
-
Saturday, September 19, 2026
-
Benign Hematology Q & A Session
-
Antithrombotic & Antiplatelet Therapy
-
Normal Coagulation
-
Coagulation Factor Deficiencies, Including von Willebrand Disease and Hemophilias
-
Hypercoagulable States
-
Q & A Panel Discussion (Coagulation, Antithrombotic Therapy)
-
Iron Deficiency and Hemochromatosis
-
Hematopoietic Growth Factors
-
Bone Marrow Failure
-
Leukopenia and Leukocytosis
-
Hemolytic Anemias
-
Q & A Panel Discussion (General Hematology Topics, Red Cell Disorders)
-



